If a patient doesn’t respond well to GLP-1s, there are other things to try. But ultimately, the medications just might not ...

We do what we believe we can do. Boost your resolutions with four research-based strategies to develop creative confidence ...

Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer – – Comprehensive Business Update and Path to Initiating Phase 2 ...

At 12, Sudarshan helped his family sell vegetables in a Maharashtra village. At 26, he is a newly qualified Chartered ...

Astronomers have discovered 3I/ATLAS, a fast-moving interstellar object detected in mid-2025. Researchers believe this ...

Kenai Therapeutics, a clinical-stage biotechnology company pioneering next generation approaches to cure neurological conditions, today announced that the California Institute for Regenerative ...

Heliophysics missions are quietly entering a pivotal phase, shifting from design and launch campaigns into […] ...

Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...

Atumelnant (80 mg) Achieved a 67% Mean Reduction in Androstenedione Levels While Simultaneously Enabling 88% of Participants Completing 12 Weeks of Treatment to Successfully Reduce Glucocorticoid Dose ...

MindRank, a clinical-stage artificial intelligence (AI)-empowered drug discovery company, today announced the initiation of "MOBILE," a pivotal Phase III clinical trial evaluating its lead candidate, ...

Amid a challenging environment, the company’s best-in-class asset base — anchored by its highly differentiated Megacampus ...

JADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026 Phase 2 ...